PMID- 9178819
OWN - NLM
STAT- MEDLINE
DCOM- 19970627
LR  - 20201222
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 71
IP  - 4
DP  - 1997 May 16
TI  - Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA 
      class-I, HLA class-II and ICAM-1 molecules.
PG  - 630-7
AB  - IL-10 is a cytokine which shows various effects including inhibition of T-cell 
      proliferation or HLA-dependent antigen presentation. In this study, we analysed 
      the effects of exogenous or autocrine IL-10 on proliferation and expression of 
      immunocritical surface molecules. Fourteen cultures of human melanoma cells were 
      established from primary melanomas, locoregional lymph-node or distant 
      metastases. In 5 melanoma cell cultures, proliferation in the presence of IL-10, 
      anti-IL-10 antibodies (Ab) or control Ab was assessed with colorimetric and 
      [3H]thymidine uptake assays. Flow cytometric analysis was used to quantify the 
      expression of human leukocyte antigen (HLA) class-I, HLA class-II and 
      intercellular adhesion molecule (ICAM)-1 and the IL-10 receptor (IL-10R). IL-10 
      production of melanoma cells was documented by RT-PCR and IL-10 protein was 
      detected in the supernatants by means of ELISA. IL-10 enhanced proliferation and 
      prolonged survival of melanoma cells in 5 out of 5 cultures. Anti-IL-10 Ab 
      decreased proliferation. IL-10R expression was found in 12 out of 14 (86%) 
      melanoma cell cultures. The expression of HLA-I, HLA-II and ICAM-1 on all 
      melanoma cells that were positive for IL-10R showed a reduction of 10-60% by 
      IL-10, whereas the surface levels of HLA-I, HLA-II and ICAM-1 in 5 out of 5 cell 
      cultures revealed an increase of 10-170% by anti-IL-10 Ab. These findings suggest 
      that IL-10 is an autocrine growth factor with significant impact on 
      immunocritical molecules in melanoma. IL-10 effects have to be considered when 
      planning therapeutic immunointerventions in melanoma patients.
FAU - Yue, F Y
AU  - Yue FY
AD  - Department of Dermatology, University of Zurich Medical School, Switzerland.
FAU - Dummer, R
AU  - Dummer R
FAU - Geertsen, R
AU  - Geertsen R
FAU - Hofbauer, G
AU  - Hofbauer G
FAU - Laine, E
AU  - Laine E
FAU - Manolio, S
AU  - Manolio S
FAU - Burg, G
AU  - Burg G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Growth Substances)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-D Antigens)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - Antibodies, Monoclonal/pharmacology
MH  - Antigens, Neoplasm/*biosynthesis/genetics
MH  - Down-Regulation/drug effects
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Genes, MHC Class I
MH  - Genes, MHC Class II
MH  - Growth Substances/*pharmacology
MH  - HLA Antigens/*biosynthesis
MH  - HLA-D Antigens/biosynthesis
MH  - Humans
MH  - Intercellular Adhesion Molecule-1/*biosynthesis/genetics
MH  - Interleukin-10/antagonists & inhibitors/immunology/*pharmacology
MH  - Lymphatic Metastasis/pathology
MH  - Melanoma/*pathology/secondary
MH  - Neoplasm Metastasis/pathology
MH  - Polymerase Chain Reaction
MH  - RNA, Messenger/biosynthesis/genetics
MH  - RNA, Neoplasm/biosynthesis/genetics
MH  - Skin Neoplasms/*pathology/secondary
MH  - Tumor Cells, Cultured/drug effects
EDAT- 1997/05/16 00:00
MHDA- 2000/06/20 09:00
CRDT- 1997/05/16 00:00
PHST- 1997/05/16 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1997/05/16 00:00 [entrez]
AID - 10.1002/(SICI)1097-0215(19970516)71:4<630::AID-IJC20>3.0.CO;2-E [pii]
AID - 10.1002/(sici)1097-0215(19970516)71:4<630::aid-ijc20>3.0.co;2-e [doi]
PST - ppublish
SO  - Int J Cancer. 1997 May 16;71(4):630-7. doi: 
      10.1002/(sici)1097-0215(19970516)71:4<630::aid-ijc20>3.0.co;2-e.